Resmed (RMD) Capital Expenditures (2009 - 2026)

Resmed (RMD) has 18 years of Capital Expenditures data on file, last reported at $33.7 million in Q1 2026.

• For the quarter ending Q1 2026, Capital Expenditures rose 61.83% year-over-year to $33.7 million; the trailing twelve-month figure through Mar 2026 stood at $135.7 million (up 61.29% YoY), and the FY2025 full-year result was $89.9 million, down 9.65% from the prior year.
• Capital Expenditures for Q1 2026 stood at $33.7 million, up from $28.5 million in the prior quarter.
• Across five years, Capital Expenditures topped out at $48.4 million in Q1 2022 and bottomed at $17.8 million in Q3 2024.
• The 5-year median for Capital Expenditures is $28.6 million (2022), against an average of $28.9 million.
• The widest annual swing landed in 2024, when Capital Expenditures tumbled 40.6%; it then jumped 140.84% in 2025.
• A 5-year view of Capital Expenditures shows it stood at $27.4 million in 2022, then declined by 14.61% to $23.4 million in 2023, then declined by 11.6% to $20.6 million in 2024, then soared by 38.24% to $28.5 million in 2025, then gained by 17.92% to $33.7 million in 2026.
• The last three Capital Expenditures figures came in at $33.7 million (Q1 2026), $28.5 million (Q4 2025), and $43.0 million (Q3 2025), per Business Quant data.

Peer Comparison